Silexion Therapeutics (SLXN) Institutional Ownership $0.92 +0.02 (+1.82%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$0.92 +0.00 (+0.25%) As of 08:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Silexion Therapeutics (NASDAQ:SLXN)CurrentInstitutional OwnershipPercentage10.95%Number ofInstitutional Buyers(last 12 months)2TotalInstitutional Inflows(last 12 months)$4.86MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$1.82M Get SLXN Insider Trade Alerts Want to know when executives and insiders are buying or selling Silexion Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Silexion Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails4/8/2025 Meyer Handelman Co.32,967$36K0.0%N/A0.392% 1/29/2025 Wildcat Capital Management LLC113,428$228K0.1%-88.9%7.089% 11/9/2024 Wildcat Capital Management LLC1,020,852$536K0.3%N/A7.381% (Data available from 1/1/2016 forward) SLXN Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of SLXN shares? During the previous two years, the following institutional investors and hedge funds held shares of Silexion Therapeutics shares: Wildcat Capital Management LLC ($228K), Meyer Handelman Co. ($36K).Learn more on SLXN's institutional investors. What percentage of Silexion Therapeutics stock is owned by institutional investors? 10.95% of Silexion Therapeutics stock is owned by institutional investors. Learn more on SLXN's institutional investor holdings. Which institutional investors have been buying Silexion Therapeutics stock? The following institutional investors have purchased Silexion Therapeutics stock in the last 24 months: Wildcat Capital Management LLC ($1.02M), and Meyer Handelman Co. ($32.97K). How much institutional buying is happening at Silexion Therapeutics? Institutional investors have bought a total of 1,053,819 shares in the last 24 months. This purchase volume represents approximately $4.86M in transactions. Which Silexion Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Silexion Therapeutics stock in the last 24 months: Wildcat Capital Management LLC ($907.42K). How much institutional selling is happening at Silexion Therapeutics? Institutional investors have sold a total of 907,424 shares in the last 24 months. This volume of shares sold represents approximately $1.82M in transactions. Related Companies SCYNEXIS Major Shareholders Dyadic International Major Shareholders FibroGen Major Shareholders Marinus Pharmaceuticals Major Shareholders Grace Therapeutics Major Shareholders Cadrenal Therapeutics Major Shareholders MiNK Therapeutics Major Shareholders Allakos Major Shareholders OnKure Therapeutics Major Shareholders Kezar Life Sciences Major Shareholders This page (NASDAQ:SLXN) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump + Musk = AI’s turning pointTrump may not code… but he knows how to pick winners. And according to insiders, his administration is prep...True Market Insiders | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silexion Therapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Silexion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
